En Acción Public Service Ads Target Hispanics

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

SAN ANTONIO--A number of Hispanic notables, including Olympic gold medalist Pablo Morales and actors Maria Conchita Alonso and Jesse Borrego, have recorded public service announcements aimed at Hispanics encouraging cancer screening, good nutrition, exercise, not smoking, and sun protection.

SAN ANTONIO--A number of Hispanic notables, including Olympic gold medalist Pablo Morales and actors Maria Conchita Alonso and Jesse Borrego, have recorded public service announcements aimed at Hispanics encouraging cancer screening, good nutrition, exercise, not smoking, and sun protection.

The ads have been released to national and local TV networks in six major cities with large Hispanic populations—Miami, New York, San Diego, San Francisco, Brownsville (Texas), and San Antonio.

The National Hispanic Leadership Initiative on Cancer: En Acción, a 5-year research demonstration project funded by the NCI, produced the campaign.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content